Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
04
2022
accepted:
08
11
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
24
11
2022
Statut:
epublish
Résumé
Myelodysplastic syndrome (MDS) is a heterogeneous hematopoietic stem cell disorder with thrombocytopenia. Flow cytometric immunophenotyping of blood cells has been instrumental in diagnosis as co-criteria, but the data regarding platelets remains lacking. This study aims to determine if there is a difference in surface antigen levels on platelets by comparing surface antigen levels in MDS patients and healthy control subjects. Concurrently, as flow cytometric gating can reveal the diameter of cells, this study will investigate differences in giant platelet percentage by comparing these percentages in high- and low-risk MDS patients. Twenty newly diagnosed MDS patients were enrolled in this study. Platelet surface antigen levels were determined by measuring the binding capacity of antibodies with flow cytometry. Platelets of MDS patients were shown to have a lower level of CD61 and higher levels of CD31 and CD36 than healthy controls. Judged by forward scatter (FSC), MDS patients' platelets appeared to be larger than those of healthy control subjects, whereas the MFI adjusted by diameter (MFI/FSC ratio) of CD31, CD41a, CD42a, CD42b and CD61 on platelets were lower in MDS patients than in healthy control subjects. There was a significant quantity of giant platelets found in MDS patients, and the high-risk MDS patients tended to have a higher percentage of giant platelets than low-risk patients. Conclusions: All the results indicate that MDS patients exhibit a lower antigen presentation (MFI) adjusted by diameter on platelets than healthy controls and the giant platelets detected by flow cytometry might correlate with the condition of MDS.
Identifiants
pubmed: 36409726
doi: 10.1371/journal.pone.0278040
pii: PONE-D-22-10816
pmc: PMC9678267
doi:
Substances chimiques
Antigens, Human Platelet
0
Antigens, Surface
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0278040Informations de copyright
Copyright: © 2022 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
NO - The authors have declared that no competing interests exist.
Références
Cancer Epidemiol. 2016 Jun;42:186-98
pubmed: 27090942
Oncologist. 1996;1(4):284-287
pubmed: 10388004
Blood. 2002 Jan 1;99(1):391-2
pubmed: 11783436
Haematologica. 2010 Dec;95(12):2005-12
pubmed: 20713462
Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):237-41
pubmed: 21575929
Am J Hematol. 2017 Nov;92(11):E631-E634
pubmed: 28741674
Blood. 1988 May;71(5):1244-52
pubmed: 3359043
J Thromb Haemost. 2020 Jun;18(6):1256-1267
pubmed: 32108994
Blood. 2012 Apr 12;119(15):3595-603
pubmed: 22234683
Blood. 2007 May 15;109(10):4237-44
pubmed: 17234740
Leukemia. 2006 Apr;20(4):549-55
pubmed: 16498394
Leuk Res. 2011 Jul;35(7):868-73
pubmed: 21397943
Haematologica. 2012 Jun;97(6):895-902
pubmed: 22271903
J Thromb Haemost. 2007 Jul;5 Suppl 1:318-27
pubmed: 17635743
Semin Thromb Hemost. 2021 Feb;47(1):90-101
pubmed: 33525042
Br J Haematol. 2022 Aug;198(4):693-702
pubmed: 35675970
Thromb Haemost. 2019 Mar;119(3):407-420
pubmed: 30727004
Curr Protoc Cytom. 2002 Feb;Chapter 6:Unit 6.10
pubmed: 18770767
Cell Biochem Biophys. 2010 Sep;58(1):25-30
pubmed: 20585996
Thromb Haemost. 1996 Oct;76(4):585-91
pubmed: 8903000
Blood. 1989 Aug 1;74(2):594-601
pubmed: 2752135
J Exp Med. 1981 Jul 1;154(1):88-100
pubmed: 6788894
Blood. 1996 Jun 15;87(12):4925-36
pubmed: 8652804
N Engl J Med. 2009 Nov 5;361(19):1872-85
pubmed: 19890130
PLoS One. 2018 Feb 1;13(2):e0192079
pubmed: 29389990
Cytometry B Clin Cytom. 2018 Nov;94(6):918-927
pubmed: 29790256
Blood. 2004 Nov 1;104(9):2722-7
pubmed: 15198950
J Pharmacol Sci. 2006 May;101(1):103-6
pubmed: 16682784
Am J Hematol. 1994 Feb;45(2):181-4
pubmed: 7511332
Am J Hematol. 2020 Nov;95(11):1399-1420
pubmed: 32744763
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
J Nucl Med. 1989 May;30(5):629-37
pubmed: 2497234
Leuk Lymphoma. 2013 Mar;54(3):472-5
pubmed: 22916713
J Gerontol A Biol Sci Med Sci. 2010 Apr;65(4):414-20
pubmed: 19942591
Blood. 1982 Nov;60(5):1122-31
pubmed: 7126866
Methods Mol Biol. 2013;992:207-25
pubmed: 23546716
Hematology Am Soc Hematol Educ Program. 2002;:136-61
pubmed: 12446422
Mediterr J Hematol Infect Dis. 2017 Jul 01;9(1):e2017046
pubmed: 28698789
Exp Hematol. 2022 Feb;106:31-39
pubmed: 34910941
Leuk Res. 2007 Jun;31(6):727-36
pubmed: 17257673
Eur J Haematol. 2009 Nov;83(5):477-82
pubmed: 19548919
Int J Lab Hematol. 2020 Aug;42(4):371-379
pubmed: 32202052